Jun 2015 – Jun 2020

Ethiopia National Deworming Programme

Ethiopia

Country

Ethiopia – Africa

To support the Government of Ethiopia to launch and scale up a national deworming programme that will treat 100 million children by 2020.

$18,625,000 Multi-Year Grant Value

Other funders

  • Government of Ethiopia -

  • END Fund -

  • DFID -

  • Schistosomiasis Control Initiative (SCI) -

  • Evidence Action

Ethiopia National Deworming Programme - visual

Each year for the next five years, school-age children living in endemic areas throughout the country will be treated for soil-transmitted helminths and schistosomiasis. 

The Federal Ministries of Health and Education will partner to train teachers and Health Extension Workers to deliver deworming treatments to children.  

In November 2015, 16.5 million children are targeted for treatment. Treatments will be scaled up each year with a target of reaching 26.1 million children annually (80% of all at-risk children) by 2020. 

The programme will focus on building the technical capacity to deliver treatments and monitor their impact, ensuring data-driven decision making and high-quality programming.  


The Schistosomiasis Control Initiative, in collaboration with Evidence Action, provides technical assistance for the implementation and monitoring of the programme to help ensure programme sustainability in the long-term.

Children at the launch of the Ethiopian National Deworming Programme

Children at the launch of Ethiopia' s national deworming programme on November 2015. (Photo credit: Evidence Action)

Impact

By the end of five years, the national deworming programme will have distributed more than 100 million treatments to children, ensuring that Ethiopian children will grow up healthier, more educated and with better prospects for long-term earnings. 

Because Ethiopia has the fifth highest number of children in the world in need of deworming treatment, the programme will also make a major contribution to reducing the global burden of worms on children, reducing the existing global treatment coverage gap by 5%.